Original Article
Sebaceous gland carcinoma
A subtle second malignancy following radiation therapy in patients with bilateral retinoblastoma
Article first published online: 9 NOV 2000
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<767::AID-CNCR20>3.0.CO;2-P
Copyright © 1998 American Cancer Society
Additional Information
How to Cite
Howrey, R. P., Lipham, W. J., Schultz, W. H., Buckley, E. G., Dutton, J. J., Klintworth, G. K. and Rosoff, P. M. (1998), Sebaceous gland carcinoma. Cancer, 83: 767–771. doi: 10.1002/(SICI)1097-0142(19980815)83:4<767::AID-CNCR20>3.0.CO;2-P
Publication History
- Issue published online: 9 NOV 2000
- Article first published online: 9 NOV 2000
- Manuscript Accepted: 4 FEB 1998
- Manuscript Received: 27 JAN 1998
- Abstract
- Article
- References
- Cited By
Keywords:
- retinoblastoma;
- sebaceous gland carcinoma;
- radiation;
- second primary neoplasms
Sebaceous gland carcinoma can occur in survivors of retinoblastoma, especially following radiation therapy. The poor prognosis associated with delayed diagnosis makes the recognition of this association important.
Abstract
BACKGROUND
Second primary malignancies are common after bilateral retinoblastoma; their estimated incidence has been as high as 51% 50 years after diagnosis. Fifteen patients who developed sebaceous gland carcinoma after radiation therapy have been reported in the literature, five of whom were treated for bilateral retinoblastoma.
METHODS
The authors conducted a retrospective chart review of patients treated for bilateral retinoblastoma at Duke University Medical Center who later developed sebaceous gland carcinoma.
RESULTS
This article reports two patients who developed sebaceous gland carcinoma after radiation therapy for bilateral retinoblastoma.
CONCLUSIONS
Delay in diagnosis is often associated with sebaceous gland carcinoma. Because high mortality is observed with metastatic disease, the recognition of this association is important for anyone who follows patients with a history of bilateral retinoblastoma or prior cranial radiation therapy. Cancer 1998;83:767-771. © 1998 American Cancer Society.

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470)